A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination With Nivolumab or Nivolumab and Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Trial Profile

A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination With Nivolumab or Nivolumab and Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Rovalpituzumab tesirine (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Sponsors AbbVie
  • Most Recent Events

    • 31 May 2017 Planned End Date changed from 2 Mar 2020 to 15 Apr 2020.
    • 28 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 30 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top